What recent performance says about Nurix Therapeutics (NRIX)

Nurix Therapeutics (NRIX) has seen mixed share performance recently, with a small gain over the past week and month, set against a negative move over the past 3 months and year to date.

At a share price of $16.03, Nurix’s short term momentum looks weak, with a 1 day share price return decline of 1.29% and a 90 day share price return decline of 16.94%, set against a 1 year total shareholder return of 75.38%, which points to earlier enthusiasm cooling recently.

If you are weighing Nurix against other healthcare names, it can be useful to see how it compares with other high potential biotech and pharma names. This might be a good moment to scan 31 healthcare AI stocks

With Nurix trading at $16.03 versus an average analyst target of about $30, and a value score of 1, the key question is whether the current discount signals an opportunity or if the market already reflects future growth.

Preferred Price-to-Sales of 23.1x: Is it justified?

Nurix currently trades on a P/S of 23.1x, which screens as expensive compared with both its own estimated fair level and typical peers in the biotech space.

The P/S ratio compares the company’s market value with its revenue and is often used for early stage or unprofitable drug developers where earnings are still negative. For a business like Nurix, which reported revenue of $71.8m and a net loss of $295.3m, the P/S ratio becomes a shorthand for how much investors are paying for each dollar of current sales while the pipeline is still in clinical stages.

Based on the available checks, Nurix’s 23.1x P/S is described as expensive versus an estimated fair P/S of 0.1x. This is a very wide gap that suggests the current share price reflects expectations far above what this fair ratio model implies the market could move toward. In addition, the same 23.1x level is higher than the US Biotechs industry average of 11.4x and above a peer group average of 14.2x, reinforcing the view that Nurix trades at a richer sales multiple than many comparable names.

Result: Price-to-Sales of 23.1x (OVERVALUED)

However, the wide gap to an estimated fair P/S, combined with ongoing net losses of $295.28m, leaves the story highly sensitive to trial or partnership setbacks.

Next Steps

Given this mix of enthusiasm and concern, it makes sense to look at the full picture yourself and decide how you feel about the balance of risks and rewards. To help you weigh both sides, take a closer look at the 2 key rewards and 2 important warning signs

Ready for more investment ideas?

If Nurix has caught your attention, do not stop here. Broaden your watchlist with a few focused stock ideas that match different investing styles.

• Target potential mispricings by scanning companies flagged as strong value opportunities with the 58 high quality undervalued stocks.
• Prioritise sleep-at-night resilience by checking out the 72 resilient stocks with low risk scores that surfaces businesses with more stable risk profiles.
• Hunt for future standouts early by reviewing the screener containing 23 high quality undiscovered gems that highlights under-the-radar names with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.